Kuros Biosurgery AG is pleased to announce that the Company has raised CHF 5.6m in additional venture capital funding, fully subscribed by the Company’s existing investors (Venture Incubator, NeoMed Management, CDC Entreprises, Genevest Consulting Group, Vinci Capital and DEFI Gestion) and some of the Company’s employees.

Including this round and corporate collaborations, Kuros has now secured a total of CHF 47m (€ 30.4m) in external financing to advance its technology and product development activities.

Kuros is a private company based in Zurich, Switzerland, developing novel therapies for biosurgery, tissue repair and regeneration. The company is a spin-off from the Swiss Federal Institute, ETHZ and University of Zurich. For more information, please visit www.kuros.ch.